GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 468.00
Bid: 466.50
Ask: 471.50
Change: -1.50 (-0.32%)
Spread: 5.00 (1.072%)
Open: 475.00
High: 478.50
Low: 468.00
Prev. Close: 469.50
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update & Notice of Results

10 Apr 2024 07:00

RNS Number : 9365J
Treatt PLC
10 April 2024
 

 

10 April 2024

 

TREATT PLC

("Treatt" or "the Group")

 

Half Year Trading Update and Notice of Results

Solid performance in H1 2024, with sales accelerating in the second quarter and year-on-year profit growth

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, announces the following trading update for the half year ended 31 March 2024 (the "Period").

HIGHLIGHTS:

· Profit before tax and exceptional items (PBTE) expected to be marginally ahead of prior year at c.£7.5m (H1 2023: £7.3m).

· H1 revenue of £72.1m (H1 2023: £76.0m), reflecting a subdued Q1 from the impact of destocking as expected and previously indicated; and an acceleration in Q2, with sales growing by 5.1% (7.7% in constant currency) compared to the same quarter in FY 2023.

· New wins in Premium products and in China, with both areas growing during H1.

· Improved net operating margin of c.11.0% (H1 2023: 10.1%), reflecting embedded cost disciplines and self-help measures

· Net debt unchanged from 30 September 2023 at £10.3m (FY 2023: £10.4m), reflecting higher citrus commodity prices and high receivables at period end from strong March sales; however good cash generation expected in H2 as receivables convert to cash

· Looking to H2, we have a solid sales order book and healthy sales pipeline

· H2 full year PBTE anticipated to be in line with the Board's expectations.

H1 2024 Performance

Revenue for the half year declined by 5.1% (2.7% decline in constant currency) to £72.1m (FY 2023: £76.0m) as anticipated. Q1, which is typically our quietest quarter, saw a decline year on year due to destocking, however sales were 5.1% ahead (7.7% in constant currency) in Q2 as destocking softened, as expected.

Heritage sales declined by 6.0% (constant currency) as citrus customers elected for cheaper alternatives because of sustained high orange oil prices. Despite this, we continue to support our customers with innovative and differentiating solutions. Within Heritage, Synthetic Aroma was up 3.9% (constant currency), which we consider to be reflective of demand returning in this category which was impacted by destocking in FY23.

Our higher margin Premium categories grew 11.6% (constant currency), with multiple wins in Tea in the North American market. Premium is typically H2 weighted, and as such we expect further sales and margin growth in the second half.

In New Markets, China grew 3.3% (constant currency), securing further wins in leading local beverage brands and we have established a broader base of local manufacturing partners. In line with our strategic ambition we have commenced the scale up of our global Treattzest manufacturing capacity, and this product will be relaunched in April.

Balance sheet

The Group ended the half year with net debt of £10.3m (FY 2023: £10.4m). We continue to focus on working capital management and have successfully reduced inventory volume by 5.6% since September 2023 (16.7% lower than the comparable period), offset by higher commodity prices and seasonal build for strategic and premium demand. An increase in receivables reflects the strong finish to the half year trading and we anticipate a reduction in net debt in the second half, in line with Board expectations.

Ryan Govender, Interim CEO, commented:

"Treatt delivered a robust performance in the first half, making good progress in line with our strategic goals. We are particularly pleased with progress in China, where we continued to invest and consolidate our position, and in our higher margin Premium categories where we have a number of active pipeline opportunities. Momentum in the second quarter was strong, and we recorded our highest ever monthly revenue in March.

As we enter the second half, we are encouraged by our solid order book and healthy sales pipeline. The Board continues to expect to report full year PBTE in line with expectations."

Notice of results

Treatt's results for the half year ended 31 March 2024 are expected to be announced on 14 May 2024.

Treatt plc +44 (0)1284 702500

Ryan Govender Interim Chief Executive Officer

Alison Sleight Interim Chief Financial Officer

 

Joint Brokers

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

 

Peel Hunt LLP +44 (0) 20 7418 8900

George Sellar

Mike Burke

 

Financial PR

MHP +44(0) 20 3128 8100

Tim Rowntree Treatt@mhpgroup.com

Eleni Menikou 

Catherine Chapman

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSDSAIAIIS
Date   Source Headline
20th May 20147:00 amRNSHalf Year Results
19th May 20149:47 amRNSVoting Rights and Capital
16th May 201412:07 pmRNSResult of EGM
16th Apr 20141:41 pmRNSNotice of EGM
9th Apr 20142:34 pmRNSDirector/PDMR Shareholding
7th Apr 201410:56 amRNSNotice of EGM
24th Feb 20145:12 pmRNSResult of AGM
10th Feb 20147:00 amRNSInterim Management Statement
31st Dec 20137:00 amRNSAnnual Information Update
23rd Dec 20134:35 pmRNSDirector/PDMR Shareholding
19th Dec 201310:32 amRNSAnnual Financial Report
13th Dec 20139:48 amRNSDirector/PDMR Shareholding
9th Dec 20137:00 amRNSFinal Results
22nd Oct 20134:22 pmRNSDirector/PDMR Shareholding
17th Oct 20132:53 pmRNSDirector/PDMR Shareholding
30th Sep 201312:54 pmRNSVoting Rights and Capital
30th Sep 20137:00 amRNSTrading Statement
26th Sep 20133:17 pmRNSDirector/PDMR Shareholding
13th Sep 201310:54 amRNSHolding(s) in Company
3rd Sep 20139:23 amRNSDirector/PDMR Shareholding
1st Aug 20137:00 amRNSInterim Management Statement
31st Jul 20132:14 pmRNSVoting Rights and Capital
29th Jul 201310:48 amRNSDirector/PDMR Shareholding
23rd Jul 20135:01 pmRNSHolding(s) in Company
15th Jul 20133:37 pmRNSDirector/PDMR Shareholding
15th Jul 201310:49 amRNSHolding(s) in Company
12th Jul 201312:50 pmRNSDirector/PDMR Shareholding
10th Jul 20134:31 pmRNSSale of Interest in Treatt plc
10th Jul 20134:28 pmRNSBovill Family Concert Party Placing
31st May 201310:17 amRNSDirector/PDMR Shareholding
28th May 20137:00 amRNSTrading Statement
24th May 201310:54 amRNSDirectorate Change
14th May 201310:56 amRNSDirector/PDMR Shareholding
13th May 20137:00 amRNSInterim Results
2nd Apr 20138:13 amRNSDirector/PDMR Shareholding
28th Mar 201312:58 pmRNSResult of EGM
28th Mar 20137:00 amRNSTrading Update
20th Mar 20137:00 amRNSShareholder Notification Regarding Treatt PLC
19th Mar 20133:16 pmRNSShareholder notification regarding Treatt plc
13th Mar 20137:23 amRNSDirector/PDMR Shareholding
4th Mar 20132:17 pmRNSNotice of EGM
1st Mar 20134:09 pmRNSHolding(s) in Company
1st Mar 201310:02 amRNSNotice of EGM
26th Feb 201310:02 amRNSResult of AGM
18th Feb 20134:18 pmRNSInterim Management Statement
18th Jan 20134:07 pmRNSDirectorate Change
31st Dec 20127:00 amRNSAnnual Information Update
21st Dec 201210:39 amRNSAnnual Financial Report
17th Dec 201211:33 amRNSDirector/PDMR Shareholding
10th Dec 20127:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.